Following my earlier post, here's a brief news article from Nature by Heidi Ledford, in which I've made a few general comments on the WHO Committee's recommendations, along with other experts. Heidi's piece gives a more rounded view of the recommendations than I could previously. For example, it addresses registries of clinical studies, and also the suggestion, previously raised in the 2018 Nuffield Report (of which I was a co-author) that leading CRISPR patentees agree to make licences conditional upon ethical use. It's an idea, but of course the fact that a person exercises a right under a patent does not mean that use is lawful anyway.